Page last updated: 2024-08-26

lopinavir and Asymptomatic Conditions

lopinavir has been researched along with Asymptomatic Conditions in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Gan, W; Gu, J; Li, H; Li, Y; Lu, C; Luo, P; Miao, H; Tian, M; Wang, J; Wang, S; Wu, M; Yao, Y; Yuan, B; Zhao, D; Zhao, X1
Ahuka-Mundeke, S; Bongo-Pasi Nswe, C; Hermans, MP; Ishoso, DK; Kayembe, JM; KoliƩ, MC; Machekano, RN; Madinga, JN; Mavungu Landu, DJ; Mbala-Kingebeni, P; Mbuyi, GM; Mellors, JW; Mills, EJ; Mofenson, L; Mukeba Tshialala, D; Mukendi, S; Muyembe-Tamfum, JJ; Nachega, JB; Nkwembe, EN; Nsio, JM; Otokoye, JO; Sam-Agudu, NA; Smith, G; Tshiasuma Pipo, M; Zumla, A1

Reviews

1 review(s) available for lopinavir and Asymptomatic Conditions

ArticleYear
Update on recommendations for the diagnosis and treatment of SARS-CoV-2 infection in children.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2020, Volume: 39, Issue:12

    Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Asymptomatic Diseases; Betacoronavirus; Biomarkers; Child; Clinical Laboratory Techniques; Coronavirus Infections; Cough; COVID-19; COVID-19 Testing; Drug Combinations; Early Diagnosis; Fever; Humans; Hydroxychloroquine; Interferon-alpha; Lopinavir; Pandemics; Pneumonia, Viral; Practice Guidelines as Topic; Ribavirin; Ritonavir; RNA, Viral; SARS-CoV-2; Severity of Illness Index; Tomography, X-Ray Computed

2020

Other Studies

1 other study(ies) available for lopinavir and Asymptomatic Conditions

ArticleYear
Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo.
    The American journal of tropical medicine and hygiene, 2020, Volume: 103, Issue:6

    Topics: Adolescent; Adult; Asymptomatic Diseases; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Democratic Republic of the Congo; Drug Combinations; Enoxaparin; Female; Hospital Mortality; Hospitalization; Hospitals; Humans; Intensive Care Units; Lopinavir; Male; Middle Aged; Obesity; Pandemics; Patient Discharge; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Ritonavir; SARS-CoV-2; Severity of Illness Index; Treatment Outcome

2020